Markets.com Logo
euEnglish
LoginSign Up

Smith and Nephew Share Price: Analysing Recent Fluctuations

Jan 2, 2024
6 min read
Table of Contents
  • 1. Corporation Overview
  • 2. Key Products and Services
  • 3. Innovation at Core
  • 4. Future Trends and Opportunities
  • 5. Smith & Nephew plc: Financial Performance in 2023
  • 6. Key Financial Highlights:
  • 7. Second Quarter 2023
  • 8. Third Quarter 2023
  • 9. Innovation and Product Development
  • 10. Operational Improvements
  • 11. Advanced Wound Management and Sports Medicine & ENT
  • 12. Outlook for Full Year 2023
  • 13. Smith and Nephew Share Price Analysis
  • 14. Bottom line

A ventilator in a medical setting, representing healthcare technology

 

British multinational medical equipment manufacturing company, Smith & Nephew plc, has sculpted a remarkable reputation since its inception in 1856. Known for its trademark innovation and perseverance, the company has grown beyond geographical boundaries to serve more than 100 countries.

From wound management to orthopaedic reconstruction, the company provides a diversified range of healthcare solutions worldwide.

 

Corporation Overview

Smith & Nephew was originally established as a small pharmacy in Hull, United Kingdom, by Thomas James Smith. Following his death in 1896, his nephew Horatio Nelson Smith took over the reins of the business, and thus was born 'Smith & Nephew'. 

The company steadily diversified its portfolio, manufacturing specialised wound dressings by World War I and subsequently moving into other healthcare sectors such as orthopaedics and endoscopy.

With a market capitalization of GBP 14.24 billion, as of 2021, Smith & Nephew operates with over 16,000 employees, a testament to its remarkable growth. 

The company's unwavering commitment to corporate responsibility and adherence to industry regulations have cemented its place as a trusted supplier to health systems and patients worldwide.

 

 

Key Products and Services

Smith & Nephew operates under three primary segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.

  1. Orthopaedics: This product line includes joint replacement systems for knees, hips, and shoulders, alongside various ancillary products such as bone cement and mixing systems. Innovations such as the recent 'POLAR3 Total Hip Solution' demonstrate a commitment to reducing pain and enhancing mobility for patients.
  2. Sports Medicine & ENT: Smith & Nephew offers arthroscopy-enabling technologies and a wide variety of repair products for tissue and bone. The company's pioneering work in visualisation platforms, as showcased by their advanced LENS 4k Surgical Imaging System, is noteworthy in this division.
  3. Advanced Wound Management: This segment provides a comprehensive set of products to enhance the wound healing process, including traditional and advanced dressings, skin care products, and therapy systems. Their groundbreaking Negative Pressure Wound Therapy (NPWT) systems have significantly improved wound healing times.

 

Innovation at Core

Smith & Nephew's philosophy echoes innovation at every level, as reflected in their cutting-edge products and services. One of the notable examples is their CORI Surgical System, which has revolutionised joint replacement surgeries with robotic assistance.

In 2020, the company introduced the Real Intelligence brand, which seeks to digitise the world of healthcare. This brand hosts a suite of interconnected digital technologies and services designed to improve patient outcomes while reducing the burden on healthcare systems.

 

Future Trends and Opportunities

Smith & Nephew is at the forefront of new healthcare technologies and treatments. The company's robust Research & Development function continues to explore areas such as regenerative medicine and digital health, and they have also been quick to adopt Artificial Intelligence in healthcare.

Furthermore, the company's unwavering focus on sustainability aligns it with the global objective of reducing waste and promoting green manufacturing practices. Smith & Nephew's dedication to operating responsibly is evident in their policies on environmental responsibility, ethical sourcing, and community support.

 

Smith & Nephew plc: Financial Performance in 2023


 

Image shows digital bars on a tablet, indicating financial analysis or data

 

Smith & Nephew plc, a leading portfolio medical technology company, has shown promising financial performance in 2023, driven by strategic initiatives and innovation.

 

Key Financial Highlights:

Second Quarter 2023

The company reported second-quarter revenue of $1,379 million, a 7.8% increase on an underlying basis from the previous year's quarter. This growth was fueled by higher elective procedure volumes and the accelerated growth in the robotics business. 

Orthopaedics revenue grew by 5.8%, and the Sports Medicine & ENT unit saw significant advancements.

Third Quarter 2023

The third quarter marked continued growth with revenue reaching $1,357 million, an 8.5% increase compared to the same period in 2022. The Orthopaedics business unit saw an 8.3% revenue increase, primarily driven by the JOURNEY II Total Knee System and POLAR3 Total Hip Solution. 

The Sports Medicine & ENT unit also performed strongly, with an 11.1% increase in revenue. Advanced Wound Management grew by 3.6%.

Innovation and Product Development

Smith & Nephew focused heavily on innovation, expecting 25 new product launches in 2023. Significant developments in the Orthopaedics sector included the expansion of the robotics-assisted CORI Surgical System and the introduction of the AETOS Shoulder System.

In Sports Medicine, the UltraTRAC QUAD ACL Reconstruction Technique was a notable advancement.

Operational Improvements

The Company made substantial progress in improving operational efficiency, including updating and standardising pricing controls, reducing the day’s sales outstanding, and manufacturing optimization.

Advanced Wound Management and Sports Medicine & ENT

These areas continued to perform above market, driven by strong product portfolios and expanding indications.

Outlook for Full Year 2023

Smith & Nephew projects its full-year underlying revenue growth to be towards the higher end of the 6.0% to 7.0% range. The expected trading margin is around 17.5%, influenced by various market dynamics including the situation in China.

 

Smith and Nephew Share Price Analysis

 

A finger points at dense text, possibly analysing a document


 

As of the latest available information, Smith and Nephew's share price shows varied performance across different stock exchanges. On the New York Stock Exchange (NYSE), the share price closed at $26.60, experiencing a minor decline of 0.71% from its previous close. 

The stock maintained this price in after-hours trading. Key metrics from the NYSE listing include a 52-week range of $21.53 to $33.09, a market capitalization of $11.616 billion, and a PE ratio of 53.20. The company offers a forward dividend yield of 2.82% with an ex-dividend date set for October 5, 2023​​.

On the London Stock Exchange (LSE), the share price was listed at 1,063.50p for selling and 1,064.50p for buying, with no change reported at the close on December 20, 2023. 

The company's year high was noted at 1,316.00p, and its year low at 887.00p. Smith and Nephew's market capitalization on the LSE is approximately £9.31 billion, and it has a P/E ratio of 16.46. The dividend yield is slightly higher at 2.94%​​.

The company, a significant player in the medical technology industry, is known for its design, manufacture, and marketing of orthopaedic devices, sports medicine, arthroscopic technologies, and wound-care solutions. 

A considerable portion of its revenue comes from orthopaedic products, followed by sports medicine and ENT, and the advanced wound therapy segment. The U.S. contributes roughly half of the company's total revenue, with other developed markets and emerging markets accounting for the rest.

 

Bottom line

Smith & Nephew is more than just a medical equipment manufacturing company. It's an organisation dedicated to improving lives with relentless innovation, responsible business practices, and a forward-looking approach. 

As they move towards the future, their focus will remain firmly on providing the highest quality products and advancing healthcare delivery around the globe. 

Join Market.com today and start trading like a pro.


Risk Warning: this article represents only the author’s views and is for reference only. It does not constitute investment advice or financial guidance, nor does it represent the stance of the Markets.com platform.When considering shares, indices, forex (foreign exchange) and commodities for trading and price predictions, remember that trading CFDs involves a significant degree of risk and could result in capital loss.Past performance is not indicative of any future results. This information is provided for informative purposes only and should not be construed to be investment advice. Trading cryptocurrency CFDs and spread bets is restricted for all UK retail clients. 

Danesh Ramuthi
Written by
Danesh Ramuthi
SHARE

Markets

  • Palladium - Cash

    chartpng

    --

    0.15%
  • EUR/USD

    chartpng

    --

    -0.02%
  • Cotton

    chartpng

    --

    0.09%
  • AUD/USD

    chartpng

    --

    -0.17%
  • Santander

    chartpng

    --

    -0.94%
  • Apple.svg

    Apple

    chartpng

    --

    -0.29%
  • easyJet

    chartpng

    --

    -0.62%
  • VIXX

    chartpng

    --

    -1.03%
  • Silver

    chartpng

    --

    -0.52%
Tags DirectoryView all
Table of Contents
  • 1. Corporation Overview
  • 2. Key Products and Services
  • 3. Innovation at Core
  • 4. Future Trends and Opportunities
  • 5. Smith & Nephew plc: Financial Performance in 2023
  • 6. Key Financial Highlights:
  • 7. Second Quarter 2023
  • 8. Third Quarter 2023
  • 9. Innovation and Product Development
  • 10. Operational Improvements
  • 11. Advanced Wound Management and Sports Medicine & ENT
  • 12. Outlook for Full Year 2023
  • 13. Smith and Nephew Share Price Analysis
  • 14. Bottom line

Related Articles

Crypto price prediction: XRP, Monero (XMR) Price, Cardano (ADA) Price

Crypto price prediction: the cryptocurrency market is characterized by its volatility and rapid changes in sentiment, making price predictions particularly challenging.

Frances Wang|about 15 hours ago

Bitcoin Price, XRP, Ethereum Fall: How to Trade Crypto CFDs?

The recent downturn in the cryptocurrency market has seen Bitcoin, XRP, and Ethereum experience significant price declines.

Ghko B|about 15 hours ago

Online Stock CFD Brokers 2025: Plus500, OANDA, StoneX One, Tickmill

Online Stock CFD Brokers 2025: as online trading continues to evolve, the landscape of stock Contract for Difference (CFD) brokers is becoming increasingly competitive.

Frances Wang|about 15 hours ago
Markets.com Logo
google playapp storeweb tradertradingView

Contact Us

support@markets.com +27 104470539

Markets

  • Forex
  • Shares
  • Commodities
  • Indices
  • Crypto
  • ETFs
  • Bonds

Trading

  • Trading Tools
  • Platform
  • Web Platform
  • App
  • TradingView
  • MT4
  • MT5
  • CFD Trading
  • CFD Asset List
  • Trading Info
  • Trading Conditions
  • Trading Hours
  • Trading Calculators
  • Economic Calendar

Learn

  • News
  • Trading Basics
  • Glossary
  • Webinars
  • Traders' Clinic
  • Education Centre

About

  • Why markets.com
  • Global Offering
  • Our Group
  • Careers
  • FAQs
  • Legal Pack
  • Safety Online
  • Complaints
  • Contact Support
  • Help Centre
  • Sitemap
  • Cookie Disclosure
  • Awards and Media

Promo

  • Gold Festival
  • Crypto Trading
  • marketsClub
  • Welcome Bonus
  • Loyal Bonus
  • Referral Bonus

Partnership

  • Affiliation
  • IB

Follow us on

  • Facebook
  • Twitter X
  • Instagram
  • Linkedin
  • Youtube
  • Threads
  • TikTok

Listed on

  • 2023 Best Trading Platform Middle East - International Business Magazine
  • 2023 Best Trading Conditions Broker - Forexing.com
  • 2023 Most Trusted Forex Broker - Forexing.com
  • 2023 Most Transparent Broker - AllForexBonus.com
  • 2024 Best Broker for Beginners, United Kingdom - Global Brands Magazine
  • 2024 Best MT4 & MT5 Trading Platform Europe  - Brands Review Magazine
  • 2024 Top Research and Education Resources Asia - Global Business and Finance Magazine
  • 2024 Leading CFD Broker Africa - Brands Review Magazine
  • 2024 Best Broker For Beginners LATAM - Global Business and Finance Magazine
  • 2024 Best Mobile Trading App MENA - Brands Review Magazine
  • 2024 Best Outstanding Value Brokerage MENA - Global Business and Finance Magazine
  • 2024 Best Broker for Customer Service MENA - Global Business and Finance Magazine
LegalLegal PackCookie DisclosureSafety Online

Payment
Methods

mastercardvisaskrillwire transferAOPAY
The www.markets.com/za/ site is operated by Markets South Africa (Pty) Ltd which is a regulated by the FSCA under license no. 46860 and licensed to operate as an Over The Counter Derivatives Provider (ODP) in terms of the Financial Markets Act no.19 of 2012. Markets South Africa (Pty) Ltd is located at BOUNDARY PLACE 18 RIVONIA ROAD, ILLOVO SANDTON, JOHANNESBURG, GAUTENG, 2196, South Africa. 

High Risk Investment Warning: Trading Foreign Exchange (Forex) and Contracts For Difference (CFDs) is highly speculative, carries a high level of risk and is not appropriate for every investor. You may sustain a loss of some or all of your invested capital, therefore, you should not speculate with capital that you cannot afford to lose. You should be aware of all the risks associated with trading on margin. Please read the full  Risk Disclosure Statement which gives you a more detailed explanation of the risks involved.

For privacy and data protection related complaints please contact us at privacy@markets.com. Please read our PRIVACY POLICY STATEMENT for more information on handling of personal data.

Markets.com operates through the following subsidiaries:

Safecap Investments Limited, which is regulated by the Cyprus Securities and Exchange Commission (“CySEC”) under license no. 092/08. Safecap is incorporated in the Republic of Cyprus under company number ΗΕ186196.

Markets International Limited is registered  in the Saint Vincent and The Grenadines (“SVG”) under the revised Laws of Saint Vincent and The Grenadines 2009, with registration number  27030 BC 2023.

Close
Close

set cookie

set cookie

We use cookies to do things like offer live chat support and show you content we think you’ll be interested in. If you’re happy with the use of cookies by markets.com, click accept.